Oncology

Latest News

AJMC Q&A with Robert Kratzke | Background image credit: ipopba - stock.adobe.com

Ensuring Coverage of Faster Biomarker Testing in Lung Cancer: Robert Kratzke, MD

By Hayden E. Klein
Robert Kratzke, MD

July 15th 2025

Robert Kratzke, MD, urged insurance providers to prioritize fast biomarker testing in non–small cell lung cancer, saying it’s both cost-effective and life-saving.

The investigators found that patients with SCLC and cachexia were more likely to have problems with treatment. | Image credit: appledesign - stock.adobe.com

Cachexia Worsens Prognosis in Older Patients With Advanced SCLC

By Jared Kaltwasser

July 9th 2025

Insurance gaps | Image Credit: iQoncept-stock.adobe.com

Insurance Gaps Threaten Cancer Treatment Success

By Maggie L. Shaw

July 7th 2025

Analyzed by birth cohort, the authors found each successive birth cohort had a 7.7% decline in SCLC rates. | Image credit: shidlovski

Decline in SCLC Incidence Expected to Accelerate Through 2050

By Jared Kaltwasser

June 29th 2025

While elevated NLR previously served as a marker of aggressive disease and poor prognosis in SCLC, its prognostic relevance appears to diminish in the context of immunotherapy-based treatment regimens. | Image credit: Crystal light - stock.adobe.com

Challenging the Prognostic Role of NLR in SCLC in the Era of Immunotherapy

By Kimberly Rath, PharmD

June 27th 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

Continuing Medical Education

July 16th 2025

The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation

1 Credit / Cardiology, Neurology

July 16th 2025

Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care

1.5 Credits / Gynecologic Cancer, Health Equity, Diversity & Inclusion, Oncology, Women's Health

More News

September 15th 2016

Oncotype DX May Not Be Economical for Decisions on Adjuvant Radiation

Surabhi Dangi-Garimella, PhD

A cost-effectiveness analysis has found that Oncotype DX may not be economical to make clinical decisions on adjuvant radiation treatment in patients with DCIS.

September 14th 2016

Intervention Improved Oncologist-Patient Communication, Not QOL or Hospice Use

Surabhi Dangi-Garimella, PhD

A study published in JAMA Oncology has found that interventions to improve patient-centered communication was successful in patients with advanced cancer, but it failed to improve quality of life (QOL), patient-physician relation, or healthcare utilization toward the end of life.

September 13th 2016

Daratumumab Lengthens PFS in Multiple Myeloma, but Increases Risk of Neutropenia

Although daratumumab reduced the risk of disease progression and death for patients with multiple myeloma, the drug was associated with a higher rate of neutropenia.

September 13th 2016

Growing Role of Genetic Counselors Could Improve Efficacy of Cancer Diagnosis and Treatment

Surabhi Dangi-Garimella, PhD

Insurance companies are making it mandatory for individuals to speak with qualified genetic counselors prior to testing for some hereditary cancers.

September 12th 2016

Study Finds Majority Users of Oregon's Death With Dignity Act Had Cancer

Surabhi Dangi-Garimella, PhD

A study presented at the 2016 Palliative Care in Oncology Symposium has found that a majority users of the provisions under Oregon's Death With Dignity Act had cancer and most of them chose to die at home.

This Week in Managed Care: September 10, 2016

September 10th 2016

This Week in Managed Care: September 10, 2016

This week, the top stories in managed care were poll results that show Hillary Clinton is more trusted than Donald Trump when it comes to healthcare, multiple studies highlighting remaining disparities in healthcare, and results of a digital diabetes self-management program.

September 9th 2016

Early Results From Juno's CAR-T Cell Therapy Promising in NHL

Surabhi Dangi-Garimella, PhD

An early-phase, dose-finding study using a defined composition of chimeric antigen receptor-T cells, in patients with non-Hodgkin lymphoma, shows promise.

September 9th 2016

5 Recent Developments in Cancer Immunotherapy

Surabhi Dangi-Garimella, PhD

An update on some of the recent developments in the field of immuno-oncology.

September 8th 2016

Family Caregivers of Cancer Patients Vulnerable to Depression, Anxiety

Surabhi Dangi-Garimella, PhD

Nearly 25% to 33% of family caregivers across the United States tend to ignore their own needs, resulting in poorer self-care and symptoms of depression and anxiety, according to a research study to be presented at the 2016 Palliative Care in Oncology Symposium.

September 8th 2016

Most US Adults Favor Prohibiting Tobacco Sales in Retail Pharmacies

More communities across the country have implemented policies prohibiting the sale of tobacco products in retail pharmacy stores in an effort to respond to pharmacists’ concerns about their professional obligation to promote health and wellness among patrons in their stores.

September 7th 2016

Panel Delivers Recommendations for the Cancer Moonshot

Surabhi Dangi-Garimella, PhD

A Blue Ribbon Panel of experts from diverse healthcare fields has provided preliminary recommendations to achieve the objectives of the government's Cancer Moonshot initiative.

September 7th 2016

Pembrolizumab's Breakthrough Toughens the Playing Field in NSCLC

Surabhi Dangi-Garimella, PhD

The FDA has accepted for priority review the supplemental Biologics License Application for Merck's pembrolizumab (Keytruda).

September 6th 2016

Whole-Brain Radiotherapy Unnecessary for Brain Metastases in Patients With NSCLC

Surabhi Dangi-Garimella, PhD

Patients with non-small cell lung cancer whose disease has metastasized to the brain can do without whole-brain radiotherapy, according to a new study published in the journal Lancet.

This Week in Managed Care: September 3, 2016

September 3rd 2016

This Week in Managed Care: September 3, 2016

This week in managed care, the top stories included proposals from CMS to shore up the Affordable Care Act's marketplaces, research that highlighted the link between duration of obesity and cancer risk for women, and the results of an FDA diabetes workshop.

September 2nd 2016

Information Disparity a Major Concern of Breast Cancer Survivors

Surabhi Dangi-Garimella, PhD

Researchers at the Sidney Kimmel Cancer Center collated concerns of African American breast cancer survivors to find that medical mistrust was a commonly raised issue.

September 1st 2016

Study Highlights Inconsistent Cancer Screening Guidelines Among High-Risk Transplant Patients

Surabhi Dangi-Garimella, PhD

Results of a new study published in the American Journal of Transplantation has found that international guidelines lack standardization on screening recommendations for solid organ transplant recipients.

September 1st 2016

Atezolizumab's Success in NSCLC Spells Further Trouble for Nivolumab

Surabhi Dangi-Garimella, PhD

Roche has announced that phase 3 results from the OAK study evaluating atezolizumab (Tecentriq) indicate improved overall survival compared with docetaxel in patients with locally advanced or metastatic non—small cell lung cancer.

August 31st 2016

COA-Commissioned Report Blames PBMs for Restricting Physician Dispensing

Surabhi Dangi-Garimella, PhD

A new report by the law firm Frier Levitt, commissioned by the Community Oncology Alliance, has found that restrictive tactics by pharmacy benefit managers, particularly in the specialty pharmacy arena, could restrict patient access to much needed medications.

August 31st 2016

Evidence-Based Oncology Looks at How the Cost of Cancer Care Affects Treatment

At what point does the cost of cancer therapy affect the results? The current issue of Evidence-Based Oncology, a publication of The American Journal of Managed Care, takes on one of today’s biggest treatment challenges: the eye-popping prices of today’s new therapies can erect barriers to care before it begins.

August 30th 2016

Translating a Radiologist's Visual Expertise Into Improving CAD

Surabhi Dangi-Garimella, PhD

Scientists at Brigham and Women’s Hospital are evaluating the depth of a trained radiologist’s eye to detect abnormalities on a mammogram, in an attempt to improve screening and earlier detection of disease.

August 30th 2016

Cancer Risk Increases the Longer a Woman Is Overweight or Obese

A study found that the longer a woman is overweight or obese, the higher the risk of developing several forms of cancer, plus the degree of being overweight plays a role in the risk of developing cancer.

August 29th 2016

PIONEER Trial: Hope for Patients With Unresectable Pancreatic Cancer

Surabhi Dangi-Garimella, PhD

Researchers at Cancer Research UK have developed a strategy to make pancreatic cancer more responsive to chemotherapy and radiation.

August 29th 2016

Infographic: How Young Adult Cancer Survivors Are Hit Hard by Treatment Costs

Laura Joszt, MA

In the August issue of Evidence-Based Oncology, The Samfund's Samantha Watson, MBA, and Michelle Landwehr, MPH, outline how young adult cancer survivors are disproportionately affected by treatment costs. This infographic breaks down the vicious cycle these patients get stuck in.

August 29th 2016

A Thaw in the US—Cuba Relation Could Yield a Lung Cancer Vaccine

Surabhi Dangi-Garimella, PhD

A vaccine, under development in Cuba for more than 2 decades, has shown potential to improve survival in patients with advanced non-small cell lung cancer.

August 26th 2016

Report in NEJM Links 8 More Cancers With Obesity

Researchers found a dose-response relationship for several cancers involved in eating, meaning the higher the weight, the greater risk of cancer.

August 26th 2016

5 Ongoing Initiatives at the FDA

Surabhi Dangi-Garimella, PhD

The FDA has several projects under its wings that can improve the regulatory aspect of drug development and healthcare overall.

August 25th 2016

Does Precision Medicine Aid or Complicate Treatment Decisions in Cancer?

Surabhi Dangi-Garimella, PhD

Based on the results of the MINDACT trial, investigators have concluded that chemotherapy is unnecessary in women with early-stage breast cancer who have a high clinical and low genomic risk of disease recurrence.

August 25th 2016

Dynamic Nature of Breast Cancer Resistance: The HER2 Switch

Surabhi Dangi-Garimella, PhD

Research at Massachusetts General Hospital has provided vital leads that can explain drug resistance observed in breast cancer.

August 24th 2016

Overdiagnosis Blamed for Global Increase in Thyroid Cancer

Surabhi Dangi-Garimella, PhD

Researchers from Italy and France have coauthored an article in the New England Journal of Medicine that blames novel diagnostic technologies, increased access to healthcare services, and increased medical surveillance for the thyroid cancer epidemic around the world

August 23rd 2016

The Final Word Is Out: Menopausal HRT Triples the Risk of Breast Cancer

Surabhi Dangi-Garimella, PhD

A new study by researchers at the Institute of Cancer Research has substantiated that hormone replacement using estrogen and progesterone increases the risk of breast cancer, especially with longer use.

...

93 94 95 96 97 98 99 100 101

...

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences^® and AJMC®.
All rights reserved.

Editorial Boards

Do Not Sell My Information

Terms & Conditions